Effect of the material of primary packaging containers on providing of visual inspection of pharmaceutical products

Introduction:Today all over the world requirements to drug quality have become more and more strict and its evaluation is one of the most important tasks. Usually input quality control of medicines and other groups of goods is carried out organoleptically (mainly visually) by authorized persons of pharmaceutical establishments. Primary packaging is one of the most critical components in this process, because it strongly influences on possibility of visual control of goods and, of coarse, it should be transparent. Aim:The aim of this article was to analyze primary packaging of some drugs and possibility of their identification and quality evaluation.Materials and Methods:Objects of this study were primary packages of 65 randomly taken drugs produced by some leading manufacturers in different dosage forms. Inspection analysis of quality of the researched medicinal products was provided in 8 steps: checking of the accompanying documents, checking quantity of the goods, organoleptic control of packaging, checking of labeling, checking of barcodes, checking of completeness, visual control of a product, composing of documentation for acceptance of the goods.Results and Conclusion:All investigated drugs passed the first 6 stages of inspection analysis positively. 46 samples among 65 (or 71%) could not be visually controlled (stage 7) and their appearance was impossible to check because of non-transparency of the containers. If in terms of dosage forms 53% of studied tablet drugs, 88% of eye drops and 100% of suppositories can not be evaluated visually

Современные подходы к ведению пациентов с крапивницей

The Union of Pediatricians of Russia together with the Russian Association of Allergologists and Clinical Immunologists and the Russian Society of Dermatovenerologists and Cosmetologists have developed new clinical guidelines for the urticaria in adults and children. Urticaria is a common disease; its various clinical variants are diagnosed in 15–25% of people in the global population, and a quarter of all cases belongs to chronic urticaria. The prevalence of acute urticaria is 20%, and 2.1–6.7% in child population, whereas acute urticaria is more common in children than in adults. The prevalence of chronic urticaria in adults in the general population is 0.7 and 1.4%, and 1.1% in children under 15 years of age, according to the systematic review and meta-analysis, respectively. This article covers features of epidemiology, etiology, and pathogenesis of the disease with particular focus on differential diagnostic search. Guidelines on treatment and step-by-step therapy scheme (both based on principles of evidencebased medicine) for pediatric patients were presented. Clarification on the analysis of the therapy efficacy and the degree of disease activity was given.Союзом педиатров России совместно с Российской ассоциацией аллергологов и иммунологов и Российским обществом дерматовенерологов и косметологов (РОДВК) разработаны новые клинические рекомендации для диагноза «крапивница» для взрослых и детей. Крапивница является распространенным заболеванием: различные ее клинические варианты диагностируются у 15–25% людей в популяции, при этом четверть случаев приходится на хроническую крапивницу. Распространенность острой крапивницы составляет 20%, среди детского населения — 2,1–6,7%, при этом острая крапивница у детей встречается чаще, чем у взрослых. По данным систематического обзора и мета-анализа, хроническая крапивница у взрослых в общей популяции составляет 0,7 и 1,4% соответственно, у детей до 15 лет — до 1,1%. В статье рассматриваются особенности эпидемиологии, этиологии и патогенеза заболевания, особое внимание уделено вопросам дифференциально-диагностического поиска. Для пациентов детского возраста приведены рекомендации по лечению согласно принципам доказательной медицины и предложена ступенчатая схема терапии. Дано четкое разъяснение к проведению анализа эффективности терапии и оценки степени активности заболевания

Alirocumab and cardiovascular outcomes after acute coronary syndrome

BACKGROUN

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

BACKGROUN